NCT00864318 (TICE) is a Phase 2 clinical trial of Paclitaxel in Germ Cell Tumors, sponsored by Institut Claudius Regaud.

Who is sponsoring NCT00864318?

NCT00864318 is sponsored by Institut Claudius Regaud.

What drugs are being tested in NCT00864318?

Interventions in NCT00864318: Paclitaxel, Ifosfamide, Carboplatine, Etoposide, cytapheresis + transfusion of autologous peripheral blood stem cells.

What condition does NCT00864318 study?

NCT00864318 studies Germ Cell Tumors.

Is NCT00864318 still recruiting?

NCT00864318 is currently completed. Last updated 14 April 2026.

Last reviewed 2026-04-14 · How we verify

NCT00864318: TICE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis

Completed Phase 2 Last updated 14 April 2026

What this trial tests

Phase 2 trial testing Paclitaxel in Germ Cell Tumors in 101 participants. Completed in 5 October 2020.

Timeline

13 March 2009

Primary endpoint
5 October 2020

5 October 2020

Quick facts

Lead sponsor	Institut Claudius Regaud
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	101
Start date	13 March 2009
Primary completion	5 October 2020
Estimated completion	5 October 2020
Sites	12 locations across France

Drugs / interventions tested

Paclitaxel — full drug profile →
Ifosfamide (IFOSFAMIDE) — full drug profile →
Carboplatine
Etoposide (etoposide) — full drug profile →
cytapheresis + transfusion of autologous peripheral blood stem cells

Conditions studied

Germ Cell Tumors — all drugs for Germ Cell Tumors →

Sponsor

Institut Claudius Regaud — full company profile →

Who can join

18 and older, any sex, with Germ Cell Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Not randomized, multicentric, national phase II trial estimating the efficacy of an intensification protocol in patients with refractory germ cell tumors with relapse and bad prognosis. Treatment consists in two Paclitaxel and Ifosfamide intensification cycles followed by three Carboplatine and Etoposide high dose cycles. The point is the individual Carboplatine adjustment to take into account inter-individual patients variability. This adaptation allow to control each patient plasmatic exposition to avoid both inacceptable toxicities (such as ear toxicity) and a low exposition losing then the benefit of this high dose protocol.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Multicentric phase II trial of TI-CE high-dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors.
Chevreau C, Massard C, Flechon A, Delva R, et al · · 2021 · cited 4× · PMID 33675184 · DOI 10.1002/cam4.3687

Verify or expand the search:

Other trials of Paclitaxel

Trials testing the same drug.

NCT07346196 — A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck · Phase 2 · not yet recruiting
NCT07441681 — Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive · Phase 3 · not yet recruiting
NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
NCT07195734 — Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer · Phase 2 · recruiting
NCT07465757 — A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC) · Phase 2 · not yet recruiting

Other recruiting trials for Germ Cell Tumors

Currently open trials in the same condition.

NCT05092451 — Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting C · Phase 1, PHASE2 · recruiting

Other Institut Claudius Regaud trials

Trials by the same sponsor.

NCT07427186 — Monitoring of Immunological Mechanisms and Biomarkers Underlying Efficacy of Immunotherapy in Patients With Early Stage · NA · not yet recruiting
NCT07233928 — Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Canc · NA · recruiting
NCT06967961 — Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers · NA · recruiting
NCT06797037 — Proof of Concept to Assess the Feasibility of a Decentralised Pathway Coordinated by the Advanced Practice Nurse for Pat · NA · recruiting
NCT06408038 — Are CK+/CD45+ Double-Positive Circulating Cells of Tumor-origin? Characterization in METAstatic Breast Cancer · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00864318 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institut Claudius Regaud
Last refreshed: 14 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00864318.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing